Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: William Burns, Christoph Franz, Steven Averbuch, Michael Kolodziek

Premium

Roche said this week that William Burns will not stand for re-election to the board of directors. The company also said that it has proposed that Christoph Franz be elected as chairman of the board, and the remaining members of the board should be re-elected.

The remaining board members include Andre Hoffman; Andreas Oeri; Pius Baschera; John Irving Bell; Paul Bulcke; DeAnne Julius; Severin Schwan; Peter Voser; Arthur Levinson; and Beatrice Weder di Mauro.


The Personalized Medicine Coalition has appointed Steven Averbuch and Michael Kolodziek to seats on its board of directors.

Averbuch is VP of translational clinical diagnostic development and pharmacodiagnostics at Bristol-Myers Squibb and Kolodziek is national medical director of Oncology Solutions.

The two new members will join the board as the terms of Joanne Armstrong and Nancy Simonian expire at the end of 2013.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.